<?xml version="1.0" encoding="ISO-8859-1"?>
<rss version="2.0">
    <channel>
        <title>PR.com Press Releases: Cornerstone BioPharma News</title>
        <description>Latest news releases from PR.com for Cornerstone BioPharma.</description>
        <link>http://www.pr.com/press-releases</link>
        <lastBuildDate>Sat, 11 Oct 2008 01:25:59 -0500</lastBuildDate>
        <image>
            <url>http://www.pr.com/images/logo_white.jpg</url>
            <title>Press Releases from PR.com</title>
            <link>http://www.pr.com/</link>
            <width>68</width>
            <height>69</height>
            <description>PR.com provides Free Press Release Distribution, &amp; is a unique Directory of Businesses, Products, Services, &amp; Jobs - in all industries.  Find Full Company Profiles.</description>
        </image>
        <copyright>© 2008 PR Worldwide, Inc.</copyright>
        <ttl>60</ttl>
        <item>
            <title>Cornerstone BioPharma, Inc. and SJ Pharmaceuticals, LLC Sign Co-Promotion Agreement</title>
            <link>http://www.pr.com/press-release/44803</link>
            <description>Cornerstone BioPharma&amp;trade;, the Triangle-based specialty pharmaceutical company currently focused on the development and commercialization of niche prescription medications in the respiratory arena, today announced it has signed a co-promotion agreement with SJ Pharmaceuticals (SJP).  This agreement names SJP as a partner in the promotion of Spectracef&amp;reg;, a broad spectrum, third-generation [PR.com - July 12, 2007]</description>
            <author>Cornerstone BioPharma</author>
            <guid isPermaLink="true">http://www.pr.com/press-release/44803</guid>
        </item>
        <item>
            <title>Cornerstone BioPharma, Inc. Obtains Exclusive Licensing Rights for Spectracef</title>
            <link>http://www.pr.com/press-release/22196</link>
            <description>Triangle-based specialty pharmaceutical company to serve $1.3 billion per year oral cephalosporin market [PR.com - November 09, 2006]</description>
            <author>Cornerstone BioPharma</author>
            <guid isPermaLink="true">http://www.pr.com/press-release/22196</guid>
        </item>
        <item>
            <title>Cornerstone BioPharma, Inc. and Athlon Pharmaceuticals Sign Co-Promotion Agreement</title>
            <link>http://www.pr.com/press-release/11869</link>
            <description>Cornerstone BioPharma&amp;trade;, the Triangle-based specialty pharmaceutical company currently focused on the development and commercialization of niche prescription medications in the respiratory arena, today announced the company has signed a co-promotion agreement with Athlon Pharmaceuticals (Athlon). This agreement names Athlon as a partner in the promotion of Balacet 325&amp;trade;, a mild-to-moderate pain medication. [PR.com - June 06, 2006]</description>
            <author>Cornerstone BioPharma</author>
            <guid isPermaLink="true">http://www.pr.com/press-release/11869</guid>
        </item>
    </channel>
</rss>
